AI Summary & Key Takeaways
AI InsightThis study showed that patients with systemic comorbidities (inflammatory or non-inflammatory) in addition to DM and/or HT experienced longer hospitalization times and needed more IVI.
📌 3 Key Takeaways
Abstract
Purpose: This paper aims to assess the clinical outcomes in patients with endophthalmitis. The effect of comorbidities on hospitalization time, treatment management, and vision gain are also examined. Methods: This retrospective study includes 40 eyes from 40 patients. Endophthalmitis was divided into two groups, exogenous and endogenous. Culture results, comorbidities, hospitalization times, treatment management, and vision gain were examined. Patients with diabetes mellitus(DM) and/or hypertension(HT) were put in Comorbidity Group 1(CG1). Patients with systemic comorbidities (inflammatory or non-inflammatory comorbidities) in addition to DM and/or HT were put in Comorbidity Group 2(CG2). Results: Endophthalmitis was of exogenous origin in 25 eyes and endogenous origin in 15 eyes. The outcomes of exogenous and endogenous groups according to various parameters are as follows: Rates of culture positivity (16.0%/20.0%), pars plana vitrectomy(PPV) (56.0%/86.7%), intravitreal injection(IVI) (44.0%/13.3%), rePPV(4.0%/20.0%), two IVIs (52.0%/6.7%), more than two IVIs (20.0%/66.7%). In the exogenous group, the mean hospitalization time in CG1 and CG2 was 7.3 ± 2.5 and 10.5 ± 2.8 days, respectively. The mean number of IVIs in CG2 was 28% more than CG1. In the endogenous group, mean hospitalization time in CG1 and CG2 was 14.3 ± 10.1 and 22.0 ± 6.7 days, respectively. The mean number of IVIs in CG2 was 86% more than CG1. Conclusions: The culture and antibiogram findings were low; therefore, we increased surgical procedures and repeated IVI. This study showed that patients with systemic comorbidities (inflammatory or non-inflammatory) in addition to DM and/or HT experienced longer hospitalization times and needed more IVI.